Ocular Therapeutix (NASDAQ:OCUL) COO Sells $103,471.84 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) COO Donald Notman sold 11,446 shares of the stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $9.04, for a total transaction of $103,471.84. Following the sale, the chief operating officer owned 366,356 shares of the company’s stock, valued at $3,311,858.24. This trade represents a 3.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Donald Notman also recently made the following trade(s):

• On Wednesday, February 4th, Donald Notman sold 6,035 shares of Ocular Therapeutix stock. The stock was sold at an average price of $8.54, for a total value of $51,538.90.
• On Monday, February 2nd, Donald Notman sold 5,455 shares of Ocular Therapeutix stock. The shares were sold at an average price of $9.14, for a total value of $49,858.70.

Ocular Therapeutix Price Performance

Ocular Therapeutix stock opened at $7.03 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 15.39 and a quick ratio of 15.32. The business has a 50 day simple moving average of $10.89 and a 200-day simple moving average of $11.71. Ocular Therapeutix, Inc. has a 12 month low of $5.78 and a 12 month high of $16.44. The stock has a market capitalization of $1.53 billion, a PE ratio of -4.88 and a beta of 0.90.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. The company had revenue of $13.25 million during the quarter, compared to the consensus estimate of $16.13 million. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. Ocular Therapeutix’s quarterly revenue was down 22.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.29) EPS. Equities analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in OCUL. Millennium Management LLC grew its stake in Ocular Therapeutix by 3,136.1% in the 3rd quarter. Millennium Management LLC now owns 3,855,706 shares of the biopharmaceutical company’s stock valued at $45,073,000 after acquiring an additional 3,736,560 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Ocular Therapeutix by 2,003.2% in the third quarter. Alliancebernstein L.P. now owns 3,424,439 shares of the biopharmaceutical company’s stock valued at $40,032,000 after purchasing an additional 3,261,619 shares in the last quarter. Avoro Capital Advisors LLC grew its position in shares of Ocular Therapeutix by 38.5% in the third quarter. Avoro Capital Advisors LLC now owns 10,250,000 shares of the biopharmaceutical company’s stock valued at $119,822,000 after purchasing an additional 2,850,000 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Ocular Therapeutix by 26.3% during the 4th quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock worth $140,523,000 after purchasing an additional 2,411,953 shares in the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of Ocular Therapeutix by 106.5% during the 4th quarter. Janus Henderson Group PLC now owns 4,229,202 shares of the biopharmaceutical company’s stock worth $51,321,000 after purchasing an additional 2,180,702 shares in the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Citigroup reiterated an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday. Jefferies Financial Group reaffirmed a “buy” rating on shares of Ocular Therapeutix in a report on Tuesday. HC Wainwright increased their price objective on Ocular Therapeutix from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Needham & Company LLC restated a “buy” rating and set a $20.00 target price on shares of Ocular Therapeutix in a research report on Monday, December 8th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $21.00 price target on shares of Ocular Therapeutix in a research note on Wednesday. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.